Yazdani Negareh, Sadeghi Ramin, Momeni-Moghaddam Hamed, Zarifmahmoudi Leili, Ehsaei Asieh
Refractive Errors Research Center, Mashhad University of Medical Sciences, Mashhad, Iran; Department of Optometry, Mashhad University of Medical Sciences, Mashhad, Iran.
Nuclear Medicine Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
J Optom. 2018 Jul-Sep;11(3):135-143. doi: 10.1016/j.optom.2017.09.001. Epub 2017 Nov 11.
The aim of the present meta-analysis is to compare the efficacy of cyclopentolate and tropicamide in controlling accommodation during refraction.
A comprehensive literature search was performed in PubMed, Scopus, Science direct and Ovid databases by the key words: "tropicamide"; "cyclopentolate"; "cycloplegia" and "cycloplegic" from inception to April 2016. Methodological quality of the literature was evaluated according to the Oxford Center for Evidence Based Medicine and modified Newcastle-Ottawa scale. Statistical analyses were performed using Comprehensive Meta-Analysis (version 2; Biostat Inc., USA).
The present meta-analysis included six studies (three randomized controlled trials and three case-control studies). Pooled standardized difference in the mean changes in the refractive error was 0.175 D [lower and upper limits: -0.089; 0.438] more plus in the cyclopentolate group compared to the tropicamide group; however, this difference was not statistically significant (p=0.194; Cochrane Q value=171.72 (p<0.05); I=95.34%). Egger's regression intercept was -5.33 (p=0.170). Considering type of refractive errors; refractive assessment procedure and age group; although cycloplegic effect of cyclopentolate was stronger than tropicamide; however, this effect was only statistically significant in children; hyperopic patients and with retinoscopy.
We suggest that tropicamide may be considered as a viable substitute for cyclopentolate due to its rapid onset of action. Although these results should be used cautiously in infants and in patients with high hyperopia or strabismus when using tropicamide as the sole cycloplegic agent especially in situations that the findings are variable or there is no consistency between the examination results and clinical manifestations of the visual problems.
本荟萃分析旨在比较环喷托酯和托吡卡胺在验光时控制调节的效果。
通过关键词“托吡卡胺”“环喷托酯”“睫状肌麻痹”和“睫状肌麻痹剂”在PubMed、Scopus、Science direct和Ovid数据库中进行全面的文献检索,检索时间从建库至2016年4月。根据牛津循证医学中心和改良的纽卡斯尔-渥太华量表对文献的方法学质量进行评估。使用综合荟萃分析软件(版本2;美国Biostat公司)进行统计分析。
本荟萃分析纳入了6项研究(3项随机对照试验和3项病例对照研究)。与托吡卡胺组相比,环喷托酯组屈光不正平均变化的合并标准化差异为0.175 D[下限和上限:-0.089;0.438],更偏向正值;然而,这种差异无统计学意义(p = 0.194;Cochrane Q值 = 171.72(p < 0.05);I² = 95.34%)。Egger回归截距为-5.33(p = 0.170)。考虑屈光不正类型、屈光评估程序和年龄组;虽然环喷托酯的睫状肌麻痹作用强于托吡卡胺;然而,这种作用仅在儿童、远视患者和使用检影法时具有统计学意义。
我们建议,由于托吡卡胺起效迅速,可将其视为环喷托酯的可行替代药物。尽管在婴儿以及高度远视或斜视患者中,尤其是在检查结果多变或视觉问题的检查结果与临床表现不一致的情况下,将托吡卡胺作为唯一的睫状肌麻痹剂时应谨慎使用这些结果。